711 related articles for article (PubMed ID: 27662632)
1. Impact of stent diameter and length on in-stent restenosis after DES vs BMS implantation in patients needing large coronary stents-A clinical and health-economic evaluation.
Zbinden R; von Felten S; Wein B; Tueller D; Kurz DJ; Reho I; Galatius S; Alber H; Conen D; Pfisterer M; Kaiser C; Eberli FR
Cardiovasc Ther; 2017 Feb; 35(1):19-25. PubMed ID: 27662632
[TBL] [Abstract][Full Text] [Related]
2. Randomized comparison of cost-saving and effectiveness of oral rapamycin plus bare-metal stents with drug-eluting stents: three-year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial.
Rodriguez AE; Rodriguez-Granillo AM; Antoniucci D; Mieres J; Fernandez-Pereira C; Rodriguez-Granillo GA; Santaera O; Rubilar B; Palacios IF; Serruys PW;
Catheter Cardiovasc Interv; 2012 Sep; 80(3):385-94. PubMed ID: 22109997
[TBL] [Abstract][Full Text] [Related]
3. Short- and long-term benefits of drug-eluting stents compared to bare metal stents even in treatment for large coronary arteries.
Yoshida T; Sakata K; Nitta Y; Taguchi T; Kaku B; Katsuda S; Shimojima M; Gamou T; Nakahashi T; Konno T; Kawashiri MA; Yamagishi M; Hayashi K
Heart Vessels; 2016 May; 31(5):635-42. PubMed ID: 25758470
[TBL] [Abstract][Full Text] [Related]
4. Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials.
Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Melgares R; Mainar V; Moreno R; Domínguez A; Sanchís J; Bethencourt A; Moreu J; Cequier A; Martí V; Otaegui I; Bastante T; Gonzalo N; Jiménez-Quevedo P; Cárdenas A; Fernández C;
Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412868
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis.
Almalla M; Pross V; Marx N; Hoffmann R
Coron Artery Dis; 2012 Nov; 23(7):492-6. PubMed ID: 22990414
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of percutaneous coronary intervention with cobalt-chromium everolimus eluting stents versus bare metal stents: Results from a patient level meta-analysis of randomized trials.
Ferko N; Ferrante G; Hasegawa JT; Schikorr T; Soleas IM; Hernandez JB; Sabaté M; Kaiser C; Brugaletta S; de la Torre Hernandez JM; Galatius S; Cequier A; Eberli F; de Belder A; Serruys PW; Valgimigli M
Catheter Cardiovasc Interv; 2017 May; 89(6):994-1002. PubMed ID: 27527508
[TBL] [Abstract][Full Text] [Related]
7. Comparison between catheter-based delivery of paclitaxel after bare-metal stenting and drug-eluting stents in coronary artery disease patients at high risk for in-stent restenosis.
El-Mokadem M; El-Ramly M; Hassan A; Boshra H; AbdelWahab A
Cardiovasc Revasc Med; 2017 Dec; 18(8):596-600. PubMed ID: 28625402
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of the real-world use of drug-eluting stents at 9-month follow-up: results from the Sicilian DES Registry.
Tamburino C; Barbagallo R; Capodanno D; di Matteo S; Colombo GL; Recchia M; Ciriminna S;
J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):322-9. PubMed ID: 19430343
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ;
JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063
[TBL] [Abstract][Full Text] [Related]
10. Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials.
Doi H; Maehara A; Mintz GS; Yu A; Wang H; Mandinov L; Popma JJ; Ellis SG; Grube E; Dawkins KD; Weissman NJ; Turco MA; Ormiston JA; Stone GW
JACC Cardiovasc Interv; 2009 Dec; 2(12):1269-75. PubMed ID: 20129555
[TBL] [Abstract][Full Text] [Related]
11. Percutaneous coronary intervention with oral sirolimus and bare metal stents has comparable safety and efficacy to treatment with drug eluting stents, but with significant cost saving: long-term follow-up results from the randomised, controlled ORAR III (Oral Rapamycin in ARgentina) study.
Rodriguez AE; Maree A; Tarragona S; Fernandez-Pereira C; Santaera O; Rodriguez Granillo AM; Rodriguez-Granillo GA; Russo-Felssen M; Kukreja N; Antoniucci D; Palacios IF; Serruys PW;
EuroIntervention; 2009 Jun; 5(2):255-64. PubMed ID: 20449934
[TBL] [Abstract][Full Text] [Related]
12. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.
Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C
J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384
[TBL] [Abstract][Full Text] [Related]
13. Bare-metal stent versus drug-eluting stent in large coronary arteries: meta-analysis of randomized controlled trials.
Geng DF; Meng Z; Yan HY; Nie RQ; Deng J; Wang JF
Catheter Cardiovasc Interv; 2013 Jun; 81(7):1087-94. PubMed ID: 22899538
[TBL] [Abstract][Full Text] [Related]
14. Safety and effectiveness of drug-eluting stents versus bare-metal stents in elderly patients with small coronary vessel disease.
Puymirat E; Mangiacapra F; Peace A; Ntarladimas Y; Conte M; Bartunek J; Vanderheyden M; Wijns W; de Bruyne B; Barbato E
Arch Cardiovasc Dis; 2013 Nov; 106(11):554-61. PubMed ID: 24231052
[TBL] [Abstract][Full Text] [Related]
15. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
Tiroch K; Mehilli J; Byrne RA; Schulz S; Massberg S; Laugwitz KL; Vorpahl M; Seyfarth M; Kastrati A;
JACC Cardiovasc Interv; 2014 Jan; 7(1):29-36. PubMed ID: 24332416
[TBL] [Abstract][Full Text] [Related]
16. The Role of Vascular Imaging in Guiding Routine Percutaneous Coronary Interventions: A Meta-Analysis of Bare Metal Stent and Drug-Eluting Stent Trials.
Alsidawi S; Effat M; Rahman S; Abdallah M; Leesar M
Cardiovasc Ther; 2015 Dec; 33(6):360-6. PubMed ID: 26363283
[TBL] [Abstract][Full Text] [Related]
17. Effects of drug-eluting stents after rotational atherectomy: evidence from a multicenter experience.
Cortese B; Piraino D; Godino C; Aranzulla T; Chizzola G; Ettori F; De Benedictis M; Colombo A
J Cardiovasc Med (Hagerstown); 2017 May; 18(5):354-358. PubMed ID: 26258723
[TBL] [Abstract][Full Text] [Related]
18. Final 5-year outcomes from the Endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents.
Kandzari DE; Leon MB; Meredith I; Fajadet J; Wijns W; Mauri L
JACC Cardiovasc Interv; 2013 May; 6(5):504-12. PubMed ID: 23602459
[TBL] [Abstract][Full Text] [Related]
19. Incidence of definite stent thrombosis or in-stent restenosis after drug-eluting stent implantation for treatment of coronary in-stent restenosis: from Western Denmark Heart Registry.
Jensen JK; Jensen LO; Terkelsen CJ; Lassen JF; Tilsted HH; Hansen KN; Maeng M; Thuesen L; Thayssen P
Catheter Cardiovasc Interv; 2013 Feb; 81(2):260-5. PubMed ID: 22511512
[TBL] [Abstract][Full Text] [Related]
20. In-stent restenosis is inhibited in a bare metal stent implanted distal to a sirolimus-eluting stent to treat a long de novo coronary lesion with small distal vessel diameter.
Obata JE; Nakamura T; Kitta Y; Saito Y; Sano K; Fujioka D; Kawabata K; Kugiyama K
Catheter Cardiovasc Interv; 2013 Nov; 82(6):E777-87. PubMed ID: 23378231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
